Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genentech to manufacture tocilizumab under contract

This article was originally published in Scrip

Executive Summary

Genentechhas entered an agreement to manufacture bulk supplies of the anti-interleukin-6 receptor antibody Actemra (tocilizumab) forChugai, its sister company under the Roche umbrella. Chugai will continue to manufacture bulk quantities and formulate the product at a facility in Japan, which was originally expected to be able to meet global demand. Rather than invest in additional domestic capacity, a decision has taken to outsource production to Genentech's Vacaville site in California, Chugai said. Actemra is already marketed in Japan for arthritis and Castleman's disease and has just been recommended for approval in the US for rheumatoid arthritis.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts